LYSTEDA Mechanism of Action
LYSTEDA has a unique MOA that acts downstream of coagulation
- LYSTEDA cannot induce clot formation
You may then wonder why LYSTEDA is contraindicated for women with active or history of thromboembolic events.
- If a patient were to have a spontaneous thrombus independent of LYSTEDA, the breakdown of that thrombus could potentially be slowed by LYSTEDA
- Because women with a history of thromboembolic disease have an increased risk for a spontaneous thrombus, they should not take LYSTEDA
- In women with heavy periods, LYSTEDA works downstream of the coagulation cascade and slows the dissolution of the fibrin, therefore reduces excessive bleeding.
- In women with heavy periods, LYSTEDA helps preserve the fibrin matrix, allowing their periods to be lighter.
- LYSTEDA cannot induce clot formation.
Click here for a short video of an expert in gynecology, Professor David F Archer, MD, discussing how LYSTEDA’s mechanism of action (MOA) works downstream from the coagulation cascade to lighten the patients’ heavy menstrual bleeding.
*Artistic interpretation of the mechanism of action and is not intended
to represent a precise visual depiction of the efficacy of LYSTEDA
Dosing & Administration »